New targeted drug shows promise for Hard-to-Treat cancers
Disease control
Completed
This early-stage study tested a new drug called PRT3789, alone or with chemotherapy (docetaxel), in people with advanced cancers that have a specific change in the SMARCA4 gene. The goal was to find a safe dose and see if the drug shrinks tumors. The study included 135 adults who…
Phase: PHASE1 • Sponsor: Prelude Therapeutics • Aim: Disease control
Last updated Apr 29, 2026 06:26 UTC